ICU (SeaStar Medical Holding) YoY EBITDA Growth: 39.10% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICU SeaStar Medical Holding Corp ICU
32 GF Score
Price $3.58
! 3 Warning Signs
View Full Analysis

What is SeaStar Medical Holding YoY EBITDA Growth?

SeaStar Medical Holding ICU +0.70% 32 YoY EBITDA Growth is 39.10% as of Jun. 2026. GuruFocus rates ICU with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. SeaStar Medical Holding's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 39.10%.

SeaStar Medical Holding's EBITDA per Share for the three months ended in Jun. 2026 was $-0.91.

SeaStar Medical Holding YoY EBITDA Growth Related Terms

SeaStar Medical Holding YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for SeaStar Medical Holding's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SeaStar Medical Holding YoY EBITDA Growth Chart

SeaStar Medical Holding Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -83,962.00 -318.65 17.55 77.37 91.32

SeaStar Medical Holding Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.02 87.22 89.21 79.45 39.10
ICU
32GF Score
SeaStar Medical Holding Corp ICU
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SeaStar Medical Holding YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

SeaStar Medical Holding's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-5.701--65.668)/ | -65.668 |
=91.32 %

SeaStar Medical Holding's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.911--1.496)/ | -1.496 |
=39.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 39.10% mean?
SeaStar Medical Holding (ICU) has a YoY EBITDA Growth of 39.10% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for SeaStar Medical Holding and its competitors.
Is SeaStar Medical Holding's YoY EBITDA Growth too high?
SeaStar Medical Holding's current YoY EBITDA Growth is 39.10%. Overall, SeaStar Medical Holding has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's YoY EBITDA Growth compare to INTS and GTBP?
SeaStar Medical Holding's YoY EBITDA Growth of 39.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for SeaStar Medical Holding and its competitors. SeaStar Medical Holding's current YoY EBITDA Growth is 39.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current YoY EBITDA Growth of 39.10%. The current YoY EBITDA Growth is 39.10%. SeaStar Medical Holding's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current YoY EBITDA Growth is 39.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SeaStar Medical Holding Business Description

Address 3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
32GF Score

Get the complete analysis for ICU

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.58
Price